세계의 호르몬 피임약 시장 : 예측(2025-2030년)

The hormonal contraceptives market is projected to grow at a CAGR of 5.38% over the forecast period, increasing from US$7.836 billion in 2025 to US$10.184 billion by 2030.

Hormonal contraception refers to contraceptive pills that utilize synthetic hormones to prevent pregnancy by inhibiting ovulation, thickening cervical mucus, and altering the uterine lining. The growth of global revenues in hormonal contraception is expected to accelerate due to the rising demand for family planning and reproductive health counseling. This trend positions hormonal contraception as a leading solution for family planning, fostering women's health and empowerment, increasing protective regulations and government initiatives for contraceptive access, and addressing the incidence of sexually transmitted diseases (STDs). These factors collectively create pressure to adhere to preventive measures.Additionally, increased investments from major players in developing new contraceptive devices, various government initiatives aimed at expanding the contraceptive market, and heightened awareness among medical professionals are significant drivers of market growth. As women become more informed about their options for preventing pregnancy, awareness-driven market growth is anticipated to rise rapidly from a previously low base.

Drivers of the Hormonal Contraceptives Market

• Introduction of Effective Hormonal Contraceptives: The demand for hormonal contraceptives is being driven by the introduction of novel and effective products. Several leading companies are investing in advanced technologies for contraceptive solutions. This shift has been particularly notable in developed countries like the United States, where products such as the NuvaRing have gained popularity. The vaginal ring offers comparable efficacy to traditional contraceptive pills but is user-friendly and only requires replacement every three weeks.

Key Geographical Trends

• North America Expected to Lead: The North American region is projected to experience significant growth in the hormonal contraceptives market during the forecast period. This growth can be attributed to a modern healthcare infrastructure, high awareness of family planning, and a wide range of available contraceptive options. The U.S. and Canada hold substantial shares of the market due to robust investments in healthcare systems, extensive research and development opportunities, and considerable consumer spending on health-related products. Furthermore, government programs and comprehensive health insurance coverage enhance access to hormonal contraceptives.

The strong network of healthcare institutions and ongoing advancements in contraceptive technology further support North America's leadership in promoting growth within the hormonal contraception market.________________________________________

Reasons for buying this report:-

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data & forecasts from 2022 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Hormonal contraceptives Market has been segmented as following:

By Product Type

• Oral Contraceptives
• Injectable Contraceptive
• Skin Patches
• Intrauterine Devices (IUDs)
• Vaginal Rings
• Emergency Contraceptive Pills

By Hormone Type

• Progestin-Only Contraceptives
• Combined Hormonal Contraceptives

By Distribution Channel

• Hospital
• Retail
• Online

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Italy
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific Region
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Taiwan
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base and Forecast Years Timeline
• 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

• 2.1. Research Design
• 2.2. Research Process

3. EXECUTIVE SUMMARY

• 3.1. Key Findings

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. The Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis
• 4.5. Analyst View

5. HORMONAL CONTRACEPTIVES MARKET BY PRODUCT TYPE

• 5.1. Introduction
• 5.2. Oral Contraceptives
• 5.3. Injectable Contraceptive
• 5.4. Skin Patches
• 5.5. Intrauterine Devices (IUDs)
• 5.6. Vaginal Rings
• 5.7. Emergency Contraceptive Pills

6. HORMONAL CONTRACEPTIVES MARKET BY HORMONE TYPE

• 6.1. Introduction
• 6.2. Progestin-Only Contraceptives
• 6.3. Combined Hormonal Contraceptives

7. HORMONAL CONTRACEPTIVES MARKET BY DISTRIBUTION CHANNEL

• 7.1. Introduction
• 7.2. Hospital
• 7.3. Retail
• 7.4. Online

8. HORMONAL CONTRACEPTIVES MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. By Product Type
  • 8.2.2. By Hormone Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
    • 8.2.4.1. United States
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
• 8.3. South America
  • 8.3.1. By Product Type
  • 8.3.2. By Hormone Type
  • 8.3.3. By Distribution Channel
  • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
• 8.4. Europe
  • 8.4.1. By Product Type
  • 8.4.2. By Hormone Type
  • 8.4.3. By Distribution Channel
  • 8.4.4. By Country
    • 8.4.4.1. United Kingdom
    • 8.4.4.2. France
    • 8.4.4.3. Germany
    • 8.4.4.4. Spain
    • 8.4.4.5. Italy
    • 8.4.4.6. Others
• 8.5. Middle East and Africa
  • 8.5.1. By Product Type
  • 8.5.2. By Hormone Type
  • 8.5.3. By Distribution Channel
  • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. UAE
    • 8.5.4.3. Israel
    • 8.5.4.4. Others
• 8.6. Asia Pacific
  • 8.6.1. By Product Type
  • 8.6.2. By Hormone Type
  • 8.6.3. By Distribution Channel
  • 8.6.4. By Country
    • 8.6.4.1. Japan
    • 8.6.4.2. China
    • 8.6.4.3. India
    • 8.6.4.4. South Korea
    • 8.6.4.5. Indonesia
    • 8.6.4.6. Thailand
    • 8.6.4.7. Taiwan
    • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Bayer AG
• 10.2. Pfizer, Inc.
• 10.3. Teva Pharmaceutical Industries Limited
• 10.4. Mylan N.V.
• 10.5. Johnson & Johnson
• 10.6. Merck & Co., Inc.
• 10.7. Church & Dwight, Co., Inc.
• 10.8. Ansell LTD.
• 10.9. Mayer Laboratories
• 10.10. The Female Health Company
• 10.11. Allergan plc
• 10.12. Afaxys, Inc.
• 10.13. Agile Therapeutics
• 10.14. Novartis AG
• 10.15. Prega International